← Eichor
Condition: Retinal Dystrophies Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Retinal Dystrophies

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

InsightRP2 Registry
Phase N/A · 1 location(s) · University of Göttingen · NCT06982417Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degener
Phase N/A · 1 location(s) · Ray Therapeutics, Inc. · NCT06375239An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease
EARLY_Phase 1 · 1 location(s) · HuidaGene Therapeutics Co., Ltd. · NCT07063251Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
Phase N/A · 8 location(s) · Ascidian Therapeutics, Inc · NCT06445322Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Caus
Phase N/A · 36 location(s) · Jaeb Center for Health Research · NCT05589714Natural History of Photoreceptor Degeneration in USH1B: Clinical Parameters and Validation of Functional Vision Tests in
Phase N/A · 1 location(s) · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingt · NCT07278843Cell Collection to Study Eye Diseases
Phase N/A · 1 location(s) · National Eye Institute (NEI) · NCT01432847Retinal Imaging in Patients With Inherited Retinal Degenerations
Phase N/A · 1 location(s) · University of California, San Francisco · NCT00254605Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
Phase 1/Phase 2 · 10 location(s) · Ascidian Therapeutics, Inc · NCT06467344A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years
Phase 1/Phase 2 · 2 location(s) · Sumitomo Pharma America, Inc. · NCT06891885Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal
Phase N/A · 1 location(s) · Ray Therapeutics, Inc. · NCT07502664SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs)
NA · 1 location(s) · Duke University · NCT06177977Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation
Phase 1/Phase 2 · 1 location(s) · Chigenovo Co., Ltd · NCT06952842Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
Phase N/A · 5 location(s) · National Human Genome Research Institute (NHGRI) · NCT00001373Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies
Phase 1/Phase 2 · 2 location(s) · Ace Cells Lab Limited · NCT06787482Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
Phase 2 · 14 location(s) · jCyte, Inc · NCT06912633Pilot Study of AuTNA I
NA · 1 location(s) · Eye & ENT Hospital of Fudan University · NCT05853107A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
Phase N/A · 12 location(s) · Astellas Pharma Global Development, Inc. · NCT07425574Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION
Phase 1 · 2 location(s) · The Foundation for Orthopaedics and Regenerative Medicine · NCT05147701VIsual Cerebral ConnecTivity On Functional Magnetic Resonance Imaging in Patients With Hereditary REtinal Dystrophies
Phase N/A · 1 location(s) · Fondation Ophtalmologique Adolphe de Rothschild · NCT04648124Evaluation of Objective Perimetry Using Chromatic Multifocal Pupillometer
Phase N/A · 1 location(s) · Sheba Medical Center · NCT02014389National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and
Phase N/A · 2 location(s) · National Eye Institute (NEI) · NCT06491615Global Registry and Natural History Study for Mitochondrial Disorders
Phase N/A · 33 location(s) · LMU Klinikum · NCT05554835North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
Phase N/A · 17 location(s) · Columbia University · NCT01694940Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa
Phase 1 · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT06936787Disulfiram for Treatment of Retinal Degeneration
Phase 1/Phase 2 · 1 location(s) · University of Washington · NCT05626920A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
Phase 2 · 5 location(s) · Kiora Pharmaceuticals, Inc. · NCT06628947EyeConic: Qualification for Cone-Optogenetics
Phase N/A · 9 location(s) · Institute of Molecular and Clinical Ophthalmology Basel · NCT05294978Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts Hospital
NA · 1 location(s) · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingt · NCT07292987
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.